Noah Greenberg, PharmD, CSP, MBA

The power of contracting...

10

While cell and gene therapies (#CGT) are undeniably expensive, their financial impact can mean something different for differently sized plans. During episode 19 of Astonishing Healthcare, Casey Stockman, PharmD (VP, PBA Services) broke down what the financial impact could be for a national plan with only a few eligible members and a smaller regional plan with one eligible member. Listen to the full podcast here: https://okt.to/b52Pls

7

💥 SUPER MSL: The Quest to Become the TOP MSL on Your Team💥 Don't miss this weeks MSL Talk podcast with Daniel Snyder, Ph.D., Senior Medical Affairs & HEOR Leader who discusses the differentiators for MSLs that will make you stand out and become the top MSL on your team. Learn more about….   👉 The qualities and differentiators of a “Super MSL” 👉 The skills and attributes that make MSLs stand out relative to their peers 👉 What common mistakes do MSLs need to avoid to 👉 What MSL Team leader should do to encourage and entice ideal MSL skills The MSL Talk Podcast is available on all podcast platforms and the MSL Talk YouTube Channel.     MSL Talk is a podcast that features helpful information for current Medical Science Liaisons, Medical Affairs leaders, job seekers looking to break into the pharmaceutical industry in their first MSL role as well as anyone interested in hearing good industry conversations and medical affairs discussions.   #msl #medicalaffairs #medicalscienceliaison #MSLtalk #careers  

32

3 Comments

🚨 10 Key Takeaways from "Behind Big Pharma's layoffs — is there an end in sight?" 🚨 1️⃣ Massive Job Losses: In 2023, the biopharma industry saw around 14,000 job losses due to layoffs. 2️⃣ Bristol Myers Squibb Cuts: The company plans to eliminate 2,200 jobs by 2025, including 860 in New Jersey. 3️⃣ Bayer Restructuring: Bayer has already reduced its workforce by 1,500, with more layoffs possible. 4️⃣ Expense Trends: Pharma companies' selling, general, and administrative expenses have stayed at 29% for decades, while R&D spending has risen from 12% to nearly 18% of revenue since 2000. 5️⃣ Funding Worries: An EY Biotech report reveals that 31% of biotechs may run out of funds within a year. 6️⃣ High-Demand Skills: Digital technology, AI, and market access skills are currently in high demand. 7️⃣ AI's Impact: An EY-Parthenon report suggests AI could drive future hiring in biopharma as it becomes crucial in drug development. 8️⃣ Economic Shifts: The European Central Bank has cut interest rates from a high of 4% as inflation decreases, while the Federal Reserve has yet to follow suit. 9️⃣ Political Uncertainty: The November 2024 election is unpredictable and could impact the industry, though effects will only be known post-election. 🔟 Future Outlook: Arda Ural of EY predicts a potential return to normalcy by 2025, with the worst of the layoffs possibly over by then. Stay tuned for more insights and trends from the biopharma industry! 💡✨ #Pharma #Biotech #Layoffs #JobMarket #AI #Innovation #Healthcare #Economy #FutureTrends

3

And we're off - IRA's impacts to the drug industry and pricing. One table offers substantial insights into "maximum fair price" and how many patients will be effected by each Brand. https://lnkd.in/gvwDMy9X

11

1 Comment